Tvardi Therapeutics
Michael Wyzga has spent 30+ years in leadership roles in the biopharma industry. He served as Chief Financial Officer at Genzyme, stewarding the company through a myriad of transactions ultimately culminating in the acquisition of Genzyme by Sanofi for $20.1 billion. He also served as President, Chief Executive Officer and board member at Radius Health, a publicly traded biopharmaceutical company targeting osteoporosis. Mr. Wyzga received an MBA from Providence College and a BS from Suffolk University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Tvardi Therapeutics
1 followers
Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians.